Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma

NCT03161756 is registered in ClinicalTrials.gov with Melanoma and Skin Cancer Trials Limited as lead sponsor.

NCT NCT03161756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03161756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 7, 2017
Completion date
December 31, 2023
Enrollment
72 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma stage iii, melanoma stage iv